Our lab showed that Trx80 levels are depleted in brains and cerebrospinal fluid (CSF) of MCI patients who later converted to AD [14], suggesting a potential use of Trx80 as a biomarker of relevance for AD progression. The gene discussed is TXN; the disease is Alzheimer disease.